Surgical immune interventions for solid malignancies - 12/10/16

Abstract |
Background |
The purpose of this study was to systematically review clinically translatable immunotherapeutic agents that are delivered regionally for solid malignancies.
Data Sources |
PubMed and ClinicalTrials.gov were searched for published and registered clinical trials, respectively. The search yielded 334 relevant publications, of which 116 articles were included for review after exclusion criteria were applied.
Conclusions |
There has been an increase in the regional administration of cell-based and viral vector–based clinical trials over the last 5 years. Surgical interventions have been developed for intrapleural, intracranial, intraperitoneal, and intratumoral routes of access to enhance the local delivery of these therapies. Multimodality therapies that combine regional immunotherapy with other local and systemic therapies are demonstrating continued growth as the field of immunotherapy continues to expand.
Le texte complet de cet article est disponible en PDF.Keywords : Regional immunotherapy, Surgical immunotherapy, Adoptive cell therapy
Plan
| This work was supported by grants from the National Institutes of Health (P30 CA008748), the Baker Street Foundation, the Mr. William H. Goodwin and Alice Goodwin, the Commonwealth Foundation for Cancer Research, the Experimental Therapeutics Center, the DallePezze Foundation, and the Stand Up To Cancer—Cancer Research Institute Cancer Immunology Translational Cancer Research grant (SU2C-AACR-DT1012). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. |
|
| The authors declare no conflicts of interest. |
Vol 212 - N° 4
P. 682 - octobre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
